tert-butyl-(S)-3-methyl-4-oxobutyrate | 202921-70-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert-butyl-(S)-3-methyl-4-oxobutyrate
• 英文别名: tert-butyl (3S)-3-methyl-4-oxobutanoate
• CAS: 202921-70-8
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: XYNBKHYWQMUUSL-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl-(S)-3-methyl-4-oxobutyrate 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 三乙胺 作用下， 生成
  参考文献：
  名称：

  Enantioselective Hydroformylation of 1-Alkenes with Commercial Ph-BPE Ligand

  摘要：

  A rhodium complex, in conjunction with commercially available Ph-BPE ligand, catalyzes the branch-selective asymmetric hydroformylation of 1-alkenes and rapidly generates alpha-chiral aldehydes. A wide range of terminal olefins Including 1-dodecene were examined, and all delivered high enantioselectivity (up to 98:2 er) as well as good branch:linear ratios (up to 15:1).

  DOI：

  10.1021/acs.orglett.5b01421
• 作为产物：
  描述：

  (S)-tert-butyl 4-hydroxy-3-methylbutanoate 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 生成 tert-butyl-(S)-3-methyl-4-oxobutyrate
  参考文献：
  名称：

  通过硅系留的复分解反应进行立体控制的两性霉素X的全合成。

  摘要：

  在这里报告的两性霉素X（1）的总合成中，需要两次酯化反应和一个RCM来形成具有挑战性的三取代C12-C13双键。按此顺序组装三个片段，没有发生RCM或该过程主要产生异构体Z。但是，首先通过Si系留复分解的新变体（使用Schrock催化剂）生成E双键，然后进行酯化和宏观内酯化步骤之后，仅获得1。

  DOI：

  10.1021/ol8021676

文献信息

• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Bemis Guy W.

  公开号：US20110015371A1

  公开（公告）日：2011-01-20

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可作为治疗白细胞介素-1介导疾病的药物，包括炎症性疾病、自身免疫性疾病和神经退行性疾病。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导疾病的方法。
• Enantioselective Hydroformylation of 1-Alkenes with Commercial Ph-BPE Ligand
  作者：Zhiyong Yu、Meredith S. Eno、Alexandra H. Annis、James P. Morken

  DOI：10.1021/acs.orglett.5b01421

  日期：2015.7.2

  A rhodium complex, in conjunction with commercially available Ph-BPE ligand, catalyzes the branch-selective asymmetric hydroformylation of 1-alkenes and rapidly generates alpha-chiral aldehydes. A wide range of terminal olefins Including 1-dodecene were examined, and all delivered high enantioselectivity (up to 98:2 er) as well as good branch:linear ratios (up to 15:1).
• Stereocontrolled Total Synthesis of Amphidinolide X via a Silicon-Tethered Metathesis Reaction
  作者：Carles Rodríguez-Escrich、Fèlix Urpí、Jaume Vilarrasa

  DOI：10.1021/ol8021676

  日期：2008.11.20

  Two esterifications and an RCM to create the challenging trisubstituted C12-C13 double bond were required in the total synthesis of amphidinolide X (1) reported here. Assembling the three fragments in this order, no RCM occurred or the process yielded mainly isomer Z. However, generating the E double bond first, by a new variant of a Si-tethered metathesis (using Schrock's catalyst), and carrying out

  在这里报告的两性霉素X（1）的总合成中，需要两次酯化反应和一个RCM来形成具有挑战性的三取代C12-C13双键。按此顺序组装三个片段，没有发生RCM或该过程主要产生异构体Z。但是，首先通过Si系留复分解的新变体（使用Schrock催化剂）生成E双键，然后进行酯化和宏观内酯化步骤之后，仅获得1。